Credit: Shutterstock photoHealth care stocks were narrowly higher, with the NYSE Health Care Sector Index rising about 0.2% and shares of health care companies in the S&P 500 ahead less than 0.1% as a group.
In company news, Genomic Health ( GHDX ) was higher Wednesday afternoon, reversing earlier declines that followed the cancer-diagnosis firm's swing to a Q3 net loss with revenue below Wall Street expectations.
During the three months ended Sept. 30, the company reported a $6.3 million net loss, or $0.20 per share, reversing a $500,000 profit during the same quarter last year but matching the Capital IQ consensus.
Revenue rose 4.7% year over year to $69.1 million, trailing analyst estimates by around $1.74 million.
GHDX shares were up about 1% at $35.59 each, matching their session high. The stock has traded within a 52-week range of $23.90 to $37.74 a share, rising 19% over the past year through Tuesday's close.
In other sector news,
(+) DIAGF, (+19.8%) Said it expects to file modular pre-market application for its theranostic treatment for septic shock during the first half of 2016 after FDA confirms regulatory pathway for the medical-device company.
(-) BIOL, (-0.1%) Narrows Q3 net loss to $3.5 mln, or $0.08 per share, improving on $4 mln net loss last year. Revenue rises 3.3% to $12.7 mln. No analyst estimates were available for comparison.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
